Press Releases | Health Monitor Liechtenstein

June 9, 2025

Liechtenstein Reaffirms Global Leadership in Stability and Philanthropy

EIN Presswire

July 28, 2025

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

GlobeNewswire, Inc.

April 15, 2025

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

GlobeNewswire, Inc.

December 19, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

GlobeNewswire, Inc.

January 5, 2026

SEALSQ C-Suite Visits India to Advance Post-Quantum Semiconductor Personalization Center, Quantum Investments, and Sovereign Space Capabilities

GlobeNewswire, Inc.

March 17, 2025

4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion

GlobeNewswire, Inc.

December 19, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

GlobeNewswire, Inc.

November 4, 2025

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea

GlobeNewswire, Inc.

October 16, 2025

bonyf AG receives the EU-MDR Certification Class IIa for PerioCream

EIN Presswire

December 16, 2025

TAP Expands International Brokerage Connectivity Across Europe, the Middle East, Africa, Asia, and Latin America

GlobeNewswire, Inc.

December 11, 2025

American Swiss Foundation Hosts Alumni Dinner During the Young Leaders Conference 2025

EIN Presswire

December 9, 2025

Trump Administration announces $12 billion Farmer Bridge payments for American farmers impacted by unfair market disruptions

Louisiana Department of Agriculture & Forestry

Owner: American Government

Louisiana Department of Agriculture & Forestry

Gov't Institution

Owned By	American Government
Year Founded	1921
Website	https://www.ldaf.state.la.us/
Domain Registration Year	2003
Access Type	open
Publication Location	United States, Louisiana, Baton Rouge
Owner Country	United States

We welcome your feedback!
If you have comments or corrections, let us know.

$Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

July 21, 2025

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

GlobeNewswire, Inc.

November 15, 2025

ThinkCareBelieve: Week 43 of America's Climb into the Golden Age

GlobeNewswire, Inc.

August 19, 2025

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

GlobeNewswire, Inc.

June 20, 2025

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

GlobeNewswire, Inc.

April 28, 2025

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire, Inc.

June 6, 2025

European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire, Inc.

February 28, 2025

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire, Inc.

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

GlobeNewswire, Inc.